

Publications Related to MIHARI

31 Mar 2023

No.	Title	Publication year
13	Use of National Database of Health Insurance Claims and Specific Health Checkups for Examining Practical Utilization and Safety Signal of a Drug to Support Regulatory Assessment on Postmarketing Drug Safety in Japan. Front. Med. 2023 Feb 23;10:1096992. (DOI: 10.3389/fmed.2023.1096992)	2023
12	Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real-World Data from the MID-NET in Japan. Clin Pharmacol Ther. 2023, 113: 924-931. (DOI: 10.1002/cpt.2850)	2023
11	Characterization of MID-NET® data for appropriate drug safety assessment : lessons learned from studies investigating incidence of decreased liver function in patients prescribed drugs for pulmonary arterial hypertension and examining real world utilization of biosimilars. Yakuzaikeigaku. 2022 Online ahead of print (DOI: 10.3820/jjpe.28.e1)	2022
10	Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Clin Transl Sci. 2023; 16: 206- 215. (DOI: 10.1111/cts.13439)	2022
9	Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET® Medical Information Database Network in Japan. Ther Innov Regul Sci. 2022 Jul;56(4):625-631. (DOI: 10.1007/s43441-022-00400-5)	2022
8	Nested Case-Control Study Utilizing MID-NET® on Thrombocytopenia Associated With Pegfilgrastim in Patients Treated With Antineoplastic Agents. Clin Pharmacol Ther. 2021 Aug;110(2):473-479. (DOI: 10.1002/cpt.2263)	2021
7	Effect of Hepatitis C Drugs on Blood Coagulability in Patients on Warfarin Using the Medical Information Database Network (MID-NET®) in Japan. (DOI: 10.1007/s43441-020-00247-8)	2021
6	Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan. Clin Pharmacol Ther. 2022 Jan;111(1):35-43. (DOI: 10.1002/cpt.2410)	2021
5	Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1166-1174. (DOI: 10.1002/pds.4847)	2019
4	The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf. 2019 May;28(5):601-608. (DOI: 10.1002/pds.4777)	2019
3	Risk of Acute Asthma Attacks Associated With Nonsteroidal Anti-inflammatory Drugs: A Self-Controlled Case Series. Ther Innov Regul Sci. 2017 May;51(3):332-341. (DOI: 10.1177/2168479016679865)	2017
2	The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan. Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):854-9. (DOI: 10.1002/pds.4032)	2016
1	Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis. Drug Saf. 2015 Jul;38(7):641-50. (DOI: 10.1007/s40264-015-0298-4)	2015